Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pharmadrug Inc C.PHRX

Alternate Symbol(s):  LMLLF

PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions.


CSE:PHRX - Post by User

Post by Goldy63on Aug 30, 2021 12:12pm
93 Views
Post# 33781754

D. Kideckel Bio . Sales, Marketing , Medical . Wowsa .

D. Kideckel Bio . Sales, Marketing , Medical . Wowsa .

David Kideckel

Kideckel, David

David Kideckel is a Managing Director and Senior Equity Research Analyst at AltaCorp Capital Inc., heading the firm’s life sciences research franchise. Prior to joining AltaCorp Capital, Dr. Kideckel was at another leading independent investment dealer, in his role as Director of Healthcare & Biotechnology, Institutional Equity Research. Dr. Kideckel is a seasoned industry executive, having spent nearly 15 years in international pharmaceutical, biotechnology and medical device companies where he held executive roles in sales, marketing, medical affairs and international business development. Dr. Kideckel holds a Ph.D. and MBA from the University of Toronto’s Institute of Medical Science and Rotman School of Management, respectively. He is a university Gold Medalist and a recipient of the Canadian Institutes of Health Research Science to Business Award.

<< Previous
Bullboard Posts
Next >>